SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549
____________________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 26, 2020


Alterola Biotech Inc.
(Exact name of registrant as specified in its charter)

 

Nevada 333-156091 TBA
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

 

340 S Lemon Ave #4041,

Walnut CA

 

91789

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: 512-821-2121

 

 

___________________________________________________

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[ ] Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)
   
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company   [ ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      [ ]

 

   
 

 

Section 5 – Corporate Governance and Management

 

Item 5.03    Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

 

Amended to Articles of Incorporation

 

On October 26, 2020, the board of directors and majority shareholders of the Company approved an amendment of the Company's Articles of Incorporation to increase the authorized common stock from 500,000,000 shares to 2,000,000,000 shares, par value $0.001 per share.

 

A copy of the Certificate of Amendment is attached hereto as Exhibit 3.1 and incorporated herein by reference.

 

Amended and Restated Bylaws

 

On October 26, 2020, the board of directors approved an amendment and restatement of the Company's bylaws. The bylaws were amended and restated to allow a majority of directors to act by written consent in lieu of a meeting.

 

A copy of the Amended and Restated Bylaws is attached hereto as Exhibit 3.2 and incorporated herein by reference.

 

Section 9 – Financial Statements and Exhibits

 

Item 9.01 Financial Statements and Exhibits

 

3.1 Certificate of Amendment

3.2 Amended and Restated Bylaws

  2  
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Alterola Biotech, Inc.

 

/s/ Larson Elmore

Larson Elmore

Chief Executive Officer

 

Date: October 27, 2020

 

  3  
 

Alterola Biotech (PK) (USOTC:ABTI)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Alterola Biotech (PK) Charts.
Alterola Biotech (PK) (USOTC:ABTI)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Alterola Biotech (PK) Charts.